title: [Association of the complex of polymorphic markers of ACE genes, aldosteron synthetase and endothelial synthetase of nitric oxide with progression of chronic glomerulonephritis].
abstract: OBJECTIVE
  To study association of the complex of polymorphic markers of ACE genes (ACE complex), aldosteron synthetase gene (CYP11B2) and endothelial synthetase of nitric oxide (NOS3) with onset, course and progression of chronic glomerulonephritis (CGN).
  
  
  METHODS
  117 CGN patients were examined. Genetic predisposition to CGN development was studied by comparison of distributions of alleles and genotypes of polymorphic markers of genes ACE, CYP11B2 and NOS3 in CGN patients and controls (n = 80) free of renal diseases and arterial hypertension (AH). The course of CGN was analysed with consideration of the following factors: AH severity, proteinuria persistence, nephritic level for 6 months and longer, immunosuppressive therapy and response to it, therapy with ACE inhibitors and/or blockers of antiotensin II receptors (ARB). CGN progression rate end point was doubling of initial blood creatinine level.
  
  
  RESULTS
  Significant differences in the incidence of the above alleles and genotypes in the patients and controls were not found. The patients were divided into two groups: group 1 consisted of 25 patients carrying the combination of alleles D+C+4a, group 2 consisted of the rest 92 patients. The groups did not differ by CGN course parameters, but renal survival was significantly lower in carriers of the allele combination D+C+4a. Cox's mono- and multifactorial regression analysis has shown that carriage of the allele combination D+C+4a is an independent riskfactor of renal survival deterioration.
  
  
  CONCLUSIONS
  No association was detected between polymorphic markers of genes ACE, CYP11B2 and NOS3 and onset of CGN. Carriage of D+C+4a allele combination is an independent factor of risk for fast progression of chronic renal failure.
authors.forename: E S
authors.initials: ES
authors.lastname: Kamysheva
authors.forename: I M
authors.initials: IM
authors.lastname: Kutyrina
authors.forename: V V
authors.initials: VV
authors.lastname: Nosikov
authors.forename: M Iu
authors.initials: MIu
authors.lastname: Shvetsov
authors.forename: N M
authors.initials: NM
authors.lastname: Gorashko
authors.forename: I V
authors.initials: IV
authors.lastname: Ignat'ev
authors.forename: O E
authors.initials: OE
authors.lastname: Voron'ko
authors.forename: V Iu
authors.initials: VIu
authors.lastname: Shilo
authors.forename: Iu G
authors.initials: IuG
authors.lastname: Aliaev
authors.forename: E M
authors.initials: EM
authors.lastname: Shilov
mesh_terms: D000328:Adult; D000483:Alleles; D015415:Biomarkers; D016022:Case-Control Studies; D002908:Chronic Disease; D019405:Cytochrome P-450 CYP11B2 / Q000235:genetics*; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D005921:Glomerulonephritis / Q000235:genetics* / Q000401:mortality / Q000503:physiopathology; D006801:Humans; D008297:Male; D019001:Nitric Oxide Synthase / Q000235:genetics*; D052250:Nitric Oxide Synthase Type III; D007703:Peptidyl-Dipeptidase A / Q000235:genetics*; D011110:Polymorphism, Genetic; D012307:Risk Factors
chemical_list: D015415:Biomarkers; C496314:NOS3 protein, human; D019001:Nitric Oxide Synthase; D052250:Nitric Oxide Synthase Type III; D019405:Cytochrome P-450 CYP11B2; D007703:Peptidyl-Dipeptidase A